Stock 1099 SINOPHARM GROUP CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Sinopharm Group Co. Ltd. Stock

Equities

1099

CNE100000FN7

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
21.2 HKD +0.95% Intraday chart for Sinopharm Group Co. Ltd. -0.47% +3.67%
May. 15 China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection MT
May. 14 China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status MT

Financials

Sales 2024 * 649B 89.58B 700B Sales 2025 * 707B 97.57B 763B Capitalization 61.27B 8.46B 66.15B
Net income 2024 * 9.63B 1.33B 10.4B Net income 2025 * 10.59B 1.46B 11.44B EV / Sales 2024 * 0.11 x
Net Debt 2024 * 11.49B 1.59B 12.41B Net Debt 2025 * 9.36B 1.29B 10.1B EV / Sales 2025 * 0.1 x
P/E ratio 2024 *
6.36 x
P/E ratio 2025 *
5.78 x
Employees 115,959
Yield 2024 *
4.76%
Yield 2025 *
5.23%
Free-Float 42.99%
More Fundamentals * Assessed data

Chart Sinopharm Group Co. Ltd.

Dynamic Chart

Latest news about Sinopharm Group Co. Ltd.

China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection MT
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status MT
Wall Street Cues, Property Outlooks Lift Asian Stock Markets MT
China, Hong Kong stocks rise, led by property shares RE
Sinopharm Group Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit DJ
Sinopharm Group's Q1 Profit Falls as Operating Costs Rise MT
Central Bank, Tech Outlooks Lift Major Asian Stock Markets MT
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator MT
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue MT
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024 CI
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings MT
More news

Analyst Recommendations on Sinopharm Group Co. Ltd.

Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy MT
Interest Rates, Earnings, FX Roil Asian Stock Markets MT
Nomura Adjusts Sinopharm Group's Price Target to HK$33.31 From HK$36.28, Keeps at Buy MT
Nomura Adjusts Sinopharm's Price Target to HK$36.28 From HK$36.88, Keeps at Buy MT
UBS Adjusts Sinopharm Group's Price Target to HK$26 From HK$28, Keeps at Buy MT
More recommendations

Press releases Sinopharm Group Co. Ltd.

Sinopharm : 2023 Interim Results Presentation PU
Sinopharm : 2022 Annual Results Presentation PU
Sinopharm : 2022 Interim Report PU
Sinopharm : 2021 Interim Report PU
Sinopharm : FORM OF PROXY FOR DOMESTIC SHAREHOLDERS' CLASS MEETING PU
More press releases

News in other languages on Sinopharm Group Co. Ltd.

Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi
MÄRKTE ASIEN/Trotz Zinssenkung erneute Verluste in Hongkong und Schanghai
MORNING BRIEFING - USA/Asien
Borsa: Country Garden in uscita dall'Hang Seng di Hong Kong
MÄRKTE ASIEN/Erneute Abgaben in Hongkong und Schanghai
More news

Quotes and Performance

1 day+0.95%
1 week-0.47%
1 month+6.85%
3 months-3.42%
6 months+9.39%
Current year+3.67%
More quotes

Highs and lows

1 week
20.85
Extreme 20.85
21.85
1 month
19.32
Extreme 19.32
22.95
Current year
17.44
Extreme 17.44
23.00
1 year
17.44
Extreme 17.44
27.30
3 years
14.60
Extreme 14.6
28.45
5 years
14.60
Extreme 14.6
30.45
10 years
14.60
Extreme 14.6
45.65
More quotes

Managers and Directors - Sinopharm Group Co. Ltd.

Managers TitleAgeSince
Yong Liu PSD
 President 55 09-01-08
Shuang Jun Xu PRN
 Corporate Officer/Principal 55 11-02-28
Zhong Xi Cai PRN
 Corporate Officer/Principal 59 10-04-30
Members of the board TitleAgeSince
Qi Yu Chen BRD
 Director/Board Member 52 10-04-30
Xiao Hui Guan BRD
 Director/Board Member 53 19-01-10
Yi Jian Wu SEC
 Corporate Secretary 54 -
More insiders

ETFs positioned on Sinopharm Group Co. Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
2.58% 4 M€ -27.92%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
1.36% 2 M€ -18.79% -
KRANESHARES MSCI CHINA ESG LEADERS ETF - USD ETF KraneShares MSCI China ESG Leaders ETF - USD
0.48% 4 M€ -11.56%
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.47% 2 M€ -14.14%
More ETFs positioned on Sinopharm Group Co. Ltd.

Quotes

Date Price Change Volume
24-05-31 21.2 +0.95% 23,135,420
24-05-30 21 -.--% 6,280,703
24-05-29 21 -1.87% 5,666,341
24-05-28 21.4 -1.38% 3,466,646
24-05-27 21.7 +1.88% 5,373,148

Delayed Quote Hong Kong S.E., May 31, 2024 at 04:08 am EDT

More quotes

Company Profile

Sinopharm Group Co. Ltd. specialises in the distribution of pharmaceutical products and medical devices to hospitals, clinics, pharmacies and third-party distributors. The group also operates pharmacy chains. Net sales break down by activity as follows: - distribution of pharmaceutical products (71%) ; - distribution of medical devices (21.7%); - operation of directly-owned and franchised pharmacy chains (5.9%); - other (1.4%).
Sector
Pharmaceuticals
Calendar
2024-06-12 - Annual General Meeting
Related indices
HONG KONG HANG SENG
More about the company

Income Statement Evolution

More financial data

Ratings for Sinopharm Group Co. Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
19.63 CNY
Average target price
24.61 CNY
Spread / Average Target
+25.36%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+3.67% 8.46B
MCKESSON CORPORATION Stock McKesson Corporation
+23.03% 74.04B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-1.52% 24.18B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+8.55% 8.34B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-23.71% 7.64B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+15.20% 5.33B
EBOS GROUP LIMITED Stock EBOS Group Limited
-6.90% 3.92B
GALENICA AG Stock Galenica AG
+2.68% 4.12B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+5.56% 3.89B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+18.80% 3.54B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 1099 Stock